# EDGAR Filing Document

**Accession Number:** 0000885725
**File Stem:** 0000885725-26-000013
**Filing Date:** 2026-2
**Character Count:** 12262
**Document Hash:** 8f7b06177152ca8681235740da73201d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000885725-26-000013.hdr.sgml**: 20260223

**ACCESSION NUMBER**: 0000885725-26-000013

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260218

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260223

**DATE AS OF CHANGE**: 20260223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BOSTON SCIENTIFIC CORP
- **CENTRAL INDEX KEY:** 0000885725
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 042695240
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11083
- **FILM NUMBER:** 26665794

**BUSINESS ADDRESS:**
- **STREET 1:** 300 BOSTON SCIENTIFIC WAY
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752-1234
- **BUSINESS PHONE:** 508-683-4000

**MAIL ADDRESS:**
- **STREET 1:** 300 BOSTON SCIENTIFIC WAY
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752-1234

?xml version='1.0' encoding='ASCII'? bsx-20260218

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**<u>_____________________________________________________________________</u>**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**<u>_____________________________________________________________________</u>**

**Date of Report (Date of earliest event reported): February 18, 2026**

**<u>BOSTON SCIENTIFIC CORPORATION</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **<u>Delaware</u>** | **<u>1-11083</u>** | **<u>04-2695240</u>** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

&nbsp;&nbsp;&nbsp;&nbsp;**<u>300 Boston Scientific Way, Marlborough, Massachusetts</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>01752-1234</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(Address of principal executive offices)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Zip Code)

(**508) 683-4000**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Stock, $0.01 par value per share | BSX | New York Stock Exchange |
| 0.625% Senior Notes due 2027 | BSX27 | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;** 

**Compensatory Arrangements of Certain Officers.**

On February 18, 2026 the Board of Directors (the "<u>Board</u>") of Boston Scientific Corporation (the "<u>Company</u>"), upon the recommendation of the Nominating and Governance Committee of the Board, increased the number of directors comprising the Board from ten to twelve, and appointed each of Catherine R. Smith and Christophe P. Weber to be a director of the Company, to hold office until the next annual meeting of stockholders, in each case, effective February 18, 2026. The Board further appointed Ms. Smith to serve as a member of the Audit Committee and the Nominating and Governance Committee of the Board, and Mr. Weber to serve as a member of the Executive Compensation and Human Resources Committee and the Risk, Science and Technology Committee of the Board, in each case, effective as of February 23, 2026.

Under the Company's non-employee director compensation program (the "<u>Program</u>"), each of Ms. Smith and Mr. Weber will receive standard non-employee director compensation, prorated for the time period from the effective date of their appointment to the date of the Company's 2026 annual meeting of stockholders (the "<u>2026 Annual Meeting</u>"), which includes (i) a cash retainer of approximately $24,663 (representing the prorated amount of the Program's annual cash retainer of $125,000, which can be received in cash or an equity alternative) and (ii) an equity award valued at approximately $42,420 (representing the prorated amount of the Program's annual grant of equity having a value of $215,000) vesting at the end of their terms. The actual number of shares to be granted to each of Ms. Smith and Mr. Weber will be determined on the date of grant, March 2, 2026, which is the first business day of the month following the month in which they were appointed.

In connection with their appointment to the Board, the Company intends to enter into indemnification agreements with each of Ms. Smith and Mr. Weber in substantially the same form as the Company has entered into with each of the Company's existing directors and as previously filed with the Securities and Exchange Commission.

Neither Ms. Smith nor Mr. Weber have any arrangement or understanding with any other person pursuant to which they were appointed as a director. Neither Ms. Smith nor Mr. Weber have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

**Item 7.01 Regulation FD Disclosure.**

On February 23, 2026, the Company issued a press release (the "<u>Press Release</u>") announcing the appointment of Ms. Smith and Mr. Weber to the Board. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 8.01 Other Events.**

On February 18, 2026, the Board approved an increase to the Company's existing authorization to repurchase up to $1.0 billion of the Company's common stock, par value $0.01 per share ("<u>Common Stock</u>"), by an additional $4.0 billion. As a result, the Company is authorized to repurchase up to a total of $5.0 billion of Common Stock under the Company's stock repurchase program, all of which remains available as of the date hereof.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit No. Description** 

99.1 <u>[Press Release issued by Boston Scientific Corporation, dated February 23, 2026](boardappointmentspressrele.htm)</u>.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | |
|:---|:---|:---|:---|
| Date: | February 23, 2026 | **BOSTON SCIENTIFIC CORPORATION** | **BOSTON SCIENTIFIC CORPORATION** |
|  |  | By: | /s/ Susan Thompson |
|  |  |  | Susan Thompson |
|  |  |  | Vice President, Chief Corporate Counsel and Assistant Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

![image_0a.jpg](image_0a.jpg)

**Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors** 

Marlborough, Mass. (February 23, 2026) -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Cathy Smith and Christophe Weber to its Board of Directors, effective February 18, 2026.

Smith is a seasoned executive with deep expertise in finance, corporate strategy and operational excellence. She currently serves as chief financial officer of Starbucks. Previously, she held chief financial officer roles at Nordstrom, Bright Health, Target, Express Scripts and Walmart, supporting large, complex organizations through periods of significant growth. Smith currently serves on the board of PPG Industries. She holds an MBA from the University of Southern California and a bachelor's degree in business economics from the University of California, Santa Barbara.

Weber brings extensive global leadership experience across the pharmaceutical industry. He is the president and chief executive officer of Takeda Pharmaceutical since April 2015, retiring in June 2026. He joined Takeda in 2014 as president and chief operating officer. Prior to Takeda, Weber held roles of increasing responsibility in multiple countries at GlaxoSmithKline. He has led large-scale transformations grounded in the principles of patient and customer-centricity, helping global organizations operate more effectively while remaining focused on delivering meaningful outcomes for patients. Weber earned a doctorate in pharmacy from Université de Lyon and has an advanced degree in accounting and finance.

"We are pleased to welcome Cathy and Christophe to the board," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "Each brings deep leadership experience, strategic insight and a strong track record of value creation that will support our continued focus on innovation, disciplined growth and improving patient care worldwide."

The election of Smith and Weber to Boston Scientific's Board of Directors follows the previously announced retirements of John Sununu and Yoshiaki Fujimori from the board, who will each serve until, and will not stand for re-election at, Boston Scientific's 2026 annual meeting of stockholders.

**About Boston Scientific**

------

**Exhibit 99.1**

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at

<u>www.bostonscientific.com</u> and follow us on <u>LinkedIn</u>.

CONTACTS:

Chanel Hastings

Media Relations

+1 (508) 382-0288<br>Chanel.Hastings@bsci.com

Lauren Tengler<br>Investor Relations

<br>+1 (508) 683-4479<br>BSXInvestorRelations@bsci.com

<br>